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ABSTRACT
Objectives: Nuclear factor-kappa beta (NF-kB) can potentially be related to certain fetal chromosomal abnormalities. This 
study aimed to determine whether the concentration of NF-kB changes in the amniotic fluid (AF) of pregnant women who 
have a high risk of fetal down syndrome (DS) results in prenatal screening and diagnosis testing.
Material and methods: 108 patients with an abnormal first trimester combined screening test (FTCST) were subjected to 
amniocentesis and fetal karyotype analysis between 16 and 20 weeks of gestation. Amniocentesis material obtained from 
86 patients conformed with our research criteria and only this was included in the study. Among the 86 amniocentesis 
results, there were 12 patients with confirmed DS. The karyotypes of the remaining patients were normal. Therefore the 
total study group was divided into two groups: patients with DS fetal karyotype (Group 1, n = 12) and patients with normal 
fetal karyotype (Group 2, n = 74). We used the ELISA method to assess the concentration of NF-kB and high sensitivity 
C-reactive protein (hsCRP) in each sample of AF.
Results: We observed significantly lower NF-kB concentrations in the AF of the women in Group 1 compared with the 
women in Group 2. Patients in Group 1 also had a higher concentration of hsCRP in their AF when compared with patients 
in Group 2. The FTCST results for patients in Group 1 showed a significantly higher risk than for those of Group 2. There were 
no statistically significant correlations detected when comparing the amniotic fluid nuclear factor-kappa beta (AF-NF-kB) 
levels with other clinical and laboratory parameters.
Conclusions: AF-NF-kB may play a role in the pathogenesis of fetal down syndrome.
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INTRODUCTION 
Human chromosomal diseases are characterized by 
chronic low- or high-grade inflammation (para-inflamma-
tion). Evaluation of AF may be a potential source of informa-
tion about the pathological pathways that are critical in the 
development of chromosomally abnormal fetuses. The re-
sults of this type of research can lead to an understanding of 
the processes of abnormal fetal development. In addition to 
karyotype analysis, molecular examination of AF can help us 
better understand the developmental stages of the fetus in 
patients with a high risk of fetal DS results in prenatal screen-
ing and diagnosis testing. The AF of pregnant women with 
fetal DS shows a high incidence of biochemical variations 
[1–3]. Although inflammatory mediators have been well 
documented in pPROM and spontaneous preterm births 
with intact membranes, the main marker of inflammation, 
NF-kB, has not been measured in the AF of pregnancies with 
a high risk of fetal DS results in prenatal screening tests.
Activation of the NF-kB pathway is involved in the patho-
genesis of chronic inflammatory diseases [4]. The deficient 
expression of immune response or inflammatory genes has 
been reported in fetuses with DS [3]. NF-kB is a stress-induc-
ible transcription factor that regulates the host’s immune 
and inflammatory responses. Nuclear factor-kB also inhibits 
apoptosis in response to DNA damage [5]. Stimulation of 
the NF-kB pathway activates the IkB kinases which phos-
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phorylate the inhibitory protein IkB. The degradation of IkB 
allows the translocation of NF-kB from the cytoplasm to the 
nucleus where it induces the expression of related genes 
[6–8]. For this reason, variations in NF-kB expression in the AF 
of pregnancies with a high risk of fetal DS results in prenatal 
screening tests were assessed and compared with those in 
pregnancies with normal karyotypes. The main objective of 
our study was to test whether NF-kB concentration alters in 
the AF of the pregnant women who have a high risk of fetal 
DS results in prenatal screening tests.
MATERIALS AND METHODS
The study was approved by the Ataturk University 
Medical Faculty Hospital review board committee (date: 
30 November 2017). We retrospectively reviewed the data of 
108 patients who had undergone amniocentesis, between 
16 and 20 weeks of gestation, for fetal karyotype analysis 
due to abnormal FTCST, in the perinat clinic of the Ataturk 
University Medical Faculty Hospital (Erzurum, Turkey), be-
tween January 2017 and August 2017. Of these 108 patients, 
only the amniocentesis material obtained from 86 patients 
who met the research criteria was included in the study. We 
measured the levels of NF-kB and hsCRP in the AF. We used 
the ELISA method to assess the concentration of NF-kB and 
hsCRP in each sample of AF.
Gestational age was determined based on the date of the 
woman’s last menstrual period and the prenatal ultrasound 
examination at the first 14 weeks of pregnancy. Those ex-
cluded from our study included pregnant women with any 
chronic or acute diseases, women taking any type of hormo-
nal or anti-inflammatory treatment, and those with vaginal, 
urinary tract or systemic symptoms suggestive of infection.
All 86 women in our study underwent amniocentesis and 
fetal karyotype analysis between 16 and 20 weeks of gesta-
tion. Ultrasound-guided transabdominal amniocentesis was 
performed and approximately 20 mL of the patient’s AF was 
aspirated for genetic analysis. 2 mL of the AF was centrifuged 
for 5 min at 3.000 cycles/min. We added 3 mL of BIOAMF-1 ba-
sal medium (Biological Industries, Israel) to the supernatants 
and stored the samples at +4 for future investigation. 
Fetal karyotype with DS was detected in 12 out of 
86 samples. The karyotypes of the remaining 74 patients 
were normal. Therefore we divided the whole study popula-
tion into two Groups: those patients with DS fetal karyotype 
(Group 1, n = 12) and patients with normal fetal karyotype 
(Group 2, n = 74). Table 1 shows the clinical and demo-
graphic characteristics of each Group of subjects. Indication 
of amniocentesis was the only abnormality in the screening 
test in 62 of the 86 patients. In the remaining twenty-four 
patients, in addition to an abnormal FTCST result, some soft 
markers of fetal DS were also detected in the ultrasound 
examination. Table 2 shows the soft markers of fetal DS in 
detail. Patients with a FTCST result greater than 1/240 was 
accepted as abnormal and high risk.
NF-kB measurement principle
AF nuclear factor kappa B p65 (NF-kB p65) levels were 
analysed by enzyme-linked immunosorbent assay. The 
Table 1. Clinical and demographic characteristics of the patients 
with normal and down syndrome fetal karyotypes
Patients with 
down syndrome 
fetal karyotype 
(Group 1) (n = 12)
Patients with 
normal fetal 
karyotype 
(Group 2) (n=74)
p value*
age [years] 32.17 ± 4.89 33.12 ± 6.16 0.283
BMI [kg/m2] 23.37 ± 1.62 25.19 ± 3.00 0.047*
gravidity 2.58 ± 1.37 3.42 ± 1.57 0.072
parity 1.50 ± 1.31 2.14 ± 1.26 0.075
gestational 
age [weeks] 17.92 ± 1.16 17.88 ± 1.02 0.884
estimated risk 
for trisomy 
21 in first 
trimester 
combined 
screening test 
result [1: rate]
1:41.83 ± 1:22.33 1:107.84 ± 1:74.36 0.001*
NF-kB [ng/mL] 0.34 ± 0.028 0.64 ± 0.072 0.022*
hsCRP [mg/L] 2.69 ± 1.55 1.62 ± 2.34 0.014*
heamoglobin 
[g/dl-1] 12.17 ± 0.89 12.02 ± 1.37 0.681
WCC [(μl)] 8545.83 ± 2015.33 8282.57 ± 1994.70 0.746
Results are given in mean ± SD. The Mann-whitney u test and t-test were used. 
A p value of < 0.05 was considered significant*. BMI — body mass index; NF-
kB — nuclear factor-kappa beta; hsCRP — high sensitivity C-reactive protein; 
WCC — white cell count
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ELISA kit we used uses the Sandwich-ELISA method. The 
ELISA was validated for AF and samples were assayed in 
duplicate. We used the Human NF-kB p65 ELISA Kit (Elabsci-
ence Biotechnology Inc., China). The sensitivity of the kit was 
0.10 ng/ml, the detection range was 0.16 -10 ng/mL, and 
the coefficient of variation was < 10%. The ELISA is specific 
for NF-kB p65 detection in biological fluids, and we did 
not observe any significant cross-reactivity or interference 
between the Human NF-kB p65 and analogues. The micro 
ELISA plate provided in the kit we used had been pre-coated 
with an antibody specific to Human NF-kB p65. Standards, or 
samples, were added to appropriate micro ELISA plate wells 
and combined with the specific antibody. Then a biotinylat-
ed detection antibody specific to Human NF-kB p65 and the 
Avidin-Horseradish Peroxidase (HRP) conjugate were succes-
sively added to each micro plate well and incubated. After 
incubation, free components were washed away. Then the 
substrate reagent was added to each well; and only those 
wells that contained Human NF-kB p65, the biotinylated 
detection antibody and the Avidin-HRP conjugate appeared 
blue in color. The enzyme-substrate reaction was terminated 
by adding Stop Solution and appeared yellow in color. The 
optical density (OD) was measured with spectrophotom-
etry at a wavelength of 450 nm ± 2 nm. The OD value was 
proportional to the concentration of Human NF-kB p65. The 
concentration of Human NF-kB p65 in the samples was 
calculated by comparing the OD of the samples with the 
standard curve. We also performed hsCRP determination: 
using an immunoturbidimetric assay, we measured hsCRP 
in the AF which was detected on the BioTek ELx800 Elisa 
Reader and BioTek ELx50 Elisa Washer.
Statistical analysis
The normal distribution of data was assessed by using 
the Kolmogrov-Smirnov test and found to be normal. The 
continuous variables were analyzed by the Mann-Whitney 
U test. The categorical data were analyzed by the student t 
test. Results were expressed as mean and standard devia-
tions (SD). For statistical analysis, calculations, and graphic 
illustrations the IBM SPSS Statistics 22.0 package was used. 
Statistical significance was accepted if the p value was less 
than 0.05 (p < 0.05).
RESULTS
The clinical and demographic characteristics of the 
pregnant women with normal and DS fetal karyotypes are 
presented in Table 1. Table 1 also presents the values of the 
mean concentrations and standard deviations of AF-NF-kB 
levels for each study Group. Table 2 shows the percent-
ages of fetal DS soft markers that were detected before 
amniocentesis. The fetal DS soft markers detected before 
amniocentesis in Group 1 were not significantly different 
from those detected in Group 2. Our results show that there 
were significant decreases in the concentration of AF-NF-kB 
levels in the AF from women with fetal DS compared with 
the study patients with healthy fetuses. Patients with fe-
tal DS also had higher AF concentrations of hsCRP when 
compared with patients with a healthy fetus with normal 
karyotypes. The FTCST showed a significantly higher risk in 
patients with fetal DS than in those patients with normal 
fetal karyotypes. The BMI of patients with fetal DS was lower 
when compared with patients with a healthy fetus. We did 
not find any statistically significant differences between 
the study Group and the contral Group when we compared 
other clinical parameters. Likewise, no significant correlation 
between AF-NF-kB levels and clinical and/or demographic 
parameters was detected.
DISCUSSION
Altered NF-kB expression may be involved in human dis-
eases [4]. Likewise, the NF-kB pathway likely plays a role in 
the pathogenesis of DS. Because many immune responses 
and inflammatory genes are expressed in DS abnormalities 
in the regulation of the amniotic fluid, NF-kB may be involved 
in the development of fetuses with DS. Therefore, measure-
ment of NF-kB in pregnancies with fetal DS could lead to 
a better understanding of the influence of DS on pregnancy 
and fetal outcomes. Here, we showed for the first time that 
there is a functioning NF-kB pathway in the AF of pregnant 
women both with and without fetal DS. It has been reported 
that the expression capacity of the immune response genes 
of cells with trisomy 21 is lower than that of euploid cells [3]. 
Concordantly, cytokines such as IL-1b (interleukin-1 beta) 
and TNF-α (tumor necrosis factor-alpha) induce the NF-kB 
pathway [6–8] which can amplify the inflammatory response 
in fetal parts. A recent study by Monika et al. showed signifi-
cantly decreased AF IL-1b levels in women with fetal DS [9]. 
They also reported that AF TNF-α levels in women with fetal 
DS were not different from those in healthy pregnant women 
Table 2. Percentages of fetal down syndrome soft markers detected 
before amniocentesis
n = 24 [%]
choroid plexus cysts 5 20.8
cleft lip and palate, gastroschisis 1 4.1
lateral cerebral ventriculomegaly 2 8.3
hydrops fetalis 5 20.8
cystic hygroma 2 8.3
fetal hyperechogenic bowel 4 16.6
increased maternal age 2 8.3
echogenic intracardiac focus 3 12.5
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with normal fetal karyotytpes. Moreover, other cytokines, 
such as interleukin-4, monocyte chemotactic protein-2, 
matrix metalloproteinase-1 and -9, transforming growth 
factor alpha and vascular endothelial growth factor-2 are all 
decreased in the AF of patients with fetal DS [9]. Likewise, 
Piotr Laudanski et al. showed that there are significant altera-
tions in the chemokine concentrations of AF of women with 
fetal DS [10]. In accordance with these findings we showed 
for the first time that AF-NF-kB levels, which are the principal 
regulatory molecules of inflammation, decrease in women 
with fetal DS, suggesting that inhibition of the NF-kB path-
way may be involved in the pathogenesis of fetal DS. NF-kB 
also stimulates the expression of inflammatory enzymes 
such as nitric oxide (NO), and the inducible cyclooxyge-
nase-2 (COX-2) [7]. Therefore, by affecting the amniotic fluid, 
NO, COX-2 and IL-1b expression and decreased levels of 
NF-kB in the AF of women with fetal DS may contribute to 
abnormal fetal development and perinatal outcomes.
NF-kB also controls the degree of cellular apoptosis and 
proliferation [11]. Many antiapoptotic genes are directly 
activated by NF-Kb [12]. Hence, decreased AF-NF-kB levels 
in women with fetal DS can lead to activation of apoptosis 
in fetal tissues. Concordantly, activation of apopitotic genes 
in the fetus and fetal parts may cause the loss of fetal growth 
control. The design and development of drugs that increase 
NF-kB levels and that induce the expression of antiapoptotic 
cellular proteins, can thus reduce apoptosis in the fetus and 
its parts. Failed NF-kB activation of the inflammatory genes 
may be an important contributor to the pathogenesis of 
abnormal fetal development in women with fetal DS. It is 
not possible to compare the results of our study with any 
other research, because of the lack of publications about 
AF-NF-kB levels in women with fetal DS. There are some 
possible explanations for the role of decreased AF-NF-kB 
levels in the pathophysiology of fetal DS. We know that 
NF-kB is a multifunctional molecule and that it does not only 
participate in the immune and inflammatory processes, but 
that it also affects other processes such as apopitosis and 
embryogenesis. Decreased AF-NF-kB levels are likely to be 
due to alterations in regulatory proteins that lead to activa-
tion of the NF-kB pathway. Hence, trisomy 21 may cause low 
expression levels of NF-kB in the nucleus of fetal cells, and 
consequently, NF-kB may be decreased in amniotic fluid. 
NF-kB plays an important role in fetal developmental 
processes such as immune responses and apopitosis which 
are largely affected by a fetus with trisomy 21 during preg-
nancy. In the present study, the AF-NF-kB levels of women 
with fetal DS were lower than those of women with a healthy 
fetus. This could indirectly confirm the role of NF-kB in the 
development of the fetus and its parts, that is disrupted in 
people with DS. Evaluation of AF-NF-kB levels as potential 
biomarkers of fetal DS can help us understand the patho-
physiology of trisomy 21. However, when reviewing the 
literature, there still exists no relevant research focused on 
the role of NF-kBs in the pathogenesis of DS. Therefore, it is 
difficult to make a definitive conclusion about the variations 
in the AF levels of NF-kB. 
CONCLUSIONS
A better understanding of the role of the AF-NF-kB path-
way may provide opportunities for the development of new 
drugs to prevent DS or its long term complications. The 
reduced levels of NF-kB in the AF might be dependent on 
embryonic cells with trisomy 21. In order to clarify the exact 
role of NF-kB in DS, additional factors that correlate with 
the clinical and laboratory findings should be measured.
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